ClinicalTrials.gg

Keratoconjunctivitis Sicca clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 85 studies for Keratoconjunctivitis Sicca across more than 10 countries. 1 are recruiting or about to start. 63 of them are mainly about Keratoconjunctivitis Sicca (how this is decided). Per ClinicalTrials.gov, last updated 2026-09-18.

Status

Completed
74
Withdrawn
5
Status unknown
3
Active, not recruiting
1
Not yet recruiting
1
Terminated
1

Phase

Phase 2
26
Phase 3
23
Phase 4
11
Phase 1
5

Where

United States
56
Spain
4
Israel
3
France
3
United Kingdom
2
Serbia
2

Who develops what

Add Keratoconjunctivitis Sicca to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 3 programs from 2 companies, 2 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.fulipiftide, Lubricant Eye Drops · BRIM Biotechnology Inc. · Phase 2 main aimNCT07078955 A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease — primary endpoint: Change from baseline in total corneal fluorescein staining (tCFS) score · 99 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Keratoconjunctivitis Sicca studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Calcineurin inhibitors 7 · Corticosteroids 3

Coming up

0phase 3 studies under way
1study finishes main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The study

Who these studies take

No Keratoconjunctivitis Sicca study is recruiting now.

Across all 85 studies, recruiting or not: 12% stop at 75 or younger and 7% at 65; 6% take children; 4% are for women only and 0% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Keratoconjunctivitis Sicca studies take

Of 12 phase 3 interventional studies under Keratoconjunctivitis Sicca, half reached primary completion within 14 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 314 mo7–18 · 12 studies——
Interventional, no phase7 mo2–17 · 10 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 85. Browse all 85 → or search them.